Edwards Lifesciences Corp

자세한 내용은 Edwards Lifesciences Corp 회사

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

회사 정보

종목 코드 EW

회사 이름Edwards Lifesciences Corp

상장일Mar 27, 2000

설립일1999

CEOMr. Bernard J. Zovighian

직원 수15800

유형Ordinary Share

회계 연도 종료Mar 27

주소One Edwards Way

도시IRVINE

증권 거래소NYSE Consolidated

국가United States of America

우편 번호92614

전화19492502500

웹사이트https://www.edwards.com

종목 코드 EW

상장일Mar 27, 2000

설립일1999

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Larry L. Wood

Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart

186.44K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.21K

+44.48%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+152.86%

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

--

Mr. Kieran T. Gallahue

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Larry L. Wood

Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart

186.44K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.21K

+44.48%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

사업별USD

이름

수익

비율

Transcatheter Aortic Valve Replacement

1.05B

74.09%

Surgical Heart Valve Therapy

250.90M

17.76%

Transcatheter Mitral and Tricuspid Therapies

115.20M

8.15%

지역별USD

이름

수익

비율

United States

838.90M

59.38%

Europe

341.80M

24.19%

Rest of the world

150.20M

10.63%

Japan

81.80M

5.79%

사업별

지역별

사업별USD

이름

수익

비율

Transcatheter Aortic Valve Replacement

1.05B

74.09%

Surgical Heart Valve Therapy

250.90M

17.76%

Transcatheter Mitral and Tricuspid Therapies

115.20M

8.15%

주식 보유 통계

마지막 업데이트: Fri, May 16

주주

주주 유형

주주

비율

The Vanguard Group, Inc.

11.75%

BlackRock Institutional Trust Company, N.A.

5.50%

Wellington Management Company, LLP

4.97%

State Street Global Advisors (US)

4.40%

JP Morgan Asset Management

2.79%

Other

70.59%

주주

비율

The Vanguard Group, Inc.

11.75%

BlackRock Institutional Trust Company, N.A.

5.50%

Wellington Management Company, LLP

4.97%

State Street Global Advisors (US)

4.40%

JP Morgan Asset Management

2.79%

Other

70.59%

주주 유형

주주

비율

Investment Advisor

43.28%

Investment Advisor/Hedge Fund

31.39%

Hedge Fund

5.44%

Research Firm

2.22%

Pension Fund

2.19%

Bank and Trust

1.92%

Sovereign Wealth Fund

1.53%

Individual Investor

0.92%

Endowment Fund

0.82%

Other

10.30%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

2586

529.26M

90.23%

-21.68M

2025Q1

2628

535.29M

91.24%

-19.91M

2024Q4

2597

531.64M

90.42%

-4.10M

2024Q3

2568

511.38M

84.93%

-20.94M

2024Q2

2559

522.19M

86.68%

-12.58M

2024Q1

2572

518.82M

86.18%

-12.08M

2023Q4

2573

509.93M

84.08%

-27.42M

2023Q3

2530

522.96M

86.03%

-18.75M

2023Q2

2517

523.54M

86.35%

-20.02M

2023Q1

2495

522.98M

86.26%

-32.79M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

The Vanguard Group, Inc.

68.94M

11.75%

+70.46K

+0.10%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

32.28M

5.5%

+544.18K

+1.71%

Mar 31, 2025

Wellington Management Company, LLP

29.13M

4.97%

-4.08M

-12.27%

Mar 31, 2025

State Street Global Advisors (US)

25.78M

4.4%

-25.16K

-0.10%

Mar 31, 2025

JP Morgan Asset Management

16.37M

2.79%

+5.61M

+52.12%

Mar 31, 2025

Citadel Advisors LLC

13.38M

2.28%

+3.96M

+42.09%

Mar 31, 2025

Geode Capital Management, L.L.C.

12.68M

2.16%

-970.48K

-7.11%

Mar 31, 2025

Jennison Associates LLC

10.09M

1.72%

+2.58M

+34.31%

Mar 31, 2025

Fisher Investments

10.10M

1.72%

+325.19K

+3.33%

Mar 31, 2025

Walter Scott & Partners Ltd.

9.06M

1.54%

-347.38K

-3.69%

Mar 31, 2025

79.330USD

Edwards Lifesciences Corp

79.330

개요

회사

금융